Saturn V Capital Takes 5.1% Stake in KalVista Pharma

TL;DR

**Saturn V Capital just bought 5.1% of KalVista, signaling institutional confidence.**

AI Summary

Saturn V Capital Management LP, an investment firm, reported owning 1,600,000 shares of KalVista Pharmaceuticals, Inc. common stock as of December 31, 2023. This represents a 5.1% ownership stake in the pharmaceutical company. This filing indicates a significant institutional investment, suggesting Saturn V Capital sees potential value in KalVista, which could be a positive signal for current and prospective shareholders.

Why It Matters

A new significant institutional investor like Saturn V Capital can bring increased scrutiny and potentially influence the company's strategic direction, which could impact stock performance.

Risk Assessment

Risk Level: low — This filing indicates a new institutional investor, which is generally seen as a positive or neutral development, not a direct risk.

Analyst Insight

A smart investor would research Saturn V Capital Management LP's investment thesis and KalVista's recent developments to understand the potential drivers behind this new significant stake, considering it a positive signal.

Key Numbers

• 1,600,000 — Shares Owned (Number of common stock shares of KalVista Pharmaceuticals, Inc. beneficially owned by Saturn V Capital Management LP.)
• 5.1% — Ownership Stake (Percentage of KalVista Pharmaceuticals, Inc.'s common stock owned by Saturn V Capital Management LP.)
• December 31, 2023 — Event Date (The date on which Saturn V Capital Management LP's ownership crossed the threshold requiring this SC 13G filing.)

Key Players & Entities

• Saturn V Capital Management LP (company) — reporting person, investment firm
• KalVista Pharmaceuticals, Inc. (company) — subject company, pharmaceutical preparations
• 1,600,000 (dollar_amount) — number of shares beneficially owned
• 5.1% (dollar_amount) — percentage of class beneficially owned
• December 31, 2023 (date) — date of event requiring filing

Forward-Looking Statements

• KalVista Pharmaceuticals, Inc. may see increased institutional interest following this disclosure. (KalVista Pharmaceuticals, Inc.) — medium confidence, target: Q2 2024

FAQ

Filing Documents

• tm245941d1_sc13g.htm (SC 13G) — 61KB
• 0001104659-24-016823.txt ( ) — 63KB

(a)

Item 1(a). Name of Issuer: Kalvista Pharmaceuticals, Inc. (the “Issuer”).

(b)

Item 1(b). Address of the Issuer's Principal Executive Offices: 55 Cambridge Parkway, Suite 901E, Cambridge, MA 02142.

(a)

Item 2(a). Name of Person Filing The names of the person filing this statement on Schedule 13G (collectively, the “Reporting Persons”) are: Saturn V Capital Management LP (“Saturn”) Xiaoying Tian

(b)

Item 2(b). Address of Principal Business Office or, if None, Residence: 919 Congress Avenue, Suite 830, Austin, TX 78701

(c)

Item 2(c). Citizenship: Saturn is a Delaware limited partnership. Xiaoying Tian is a United States citizen.

(d)

Item 2(d). Title of Class of Securities: Common Stock (the “Shares”).

(e)

Item 2(e). CUSIP Number: 483497103 CUSIP NO. 483497103 Page 5 of 7 Pages Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a: (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8). (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) x A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G); (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);Page 5 of 6 pages (j) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J) Item 4. The Shares described herein are owned by certain pooled investment vehicles and managed accounts for which Saturn serves as an investment manager. As a result, Saturn and Xiaoying Tian, as the managing member of the general partner of Saturn, may be deemed to beneficially own the Shares for the purposes of Rule 13d-3 of the Act insofar as they may be deemed to have the power to direct the voting or disposition of the Shares. Neither the filing of this Schedule nor any of its contents shall be deemed to constitute an admission that Saturn, Xiaoying Tian, or any other person is, for any purpose, the beneficial

(a)

Item 4(a). Amount Beneficially Owned: Aggregate of all Reporting Persons - 1,431,259 Saturn – 1,431,259* Xiaoying Tian - 1,431,259**

(b)

Item 4(b). Percent of Class: Aggregate of all Reporting Persons – 4.1% † Saturn – 4.1% †* Xiaoying Tian - 4.1% †** CUSIP NO. 483497103 Page 6 of 7 Pages

(c)

Item 4(c). Number of shares as to which such person has: (i) Sole power to vote or direct the vote: Saturn – 0 Xiaoying Tian - 0 (ii) Shared power to vote or to direct the vote: Saturn – 1,431,259* Xiaoying Tian - 1,431,259** (iii) Sole power to dispose or to direct the disposition of: Saturn – 0 Xiaoying Tian - 0 (iv) Shared power to dispose or to direct the disposition of: Saturn – 1,431,259* Xiaoying Tian - 1,431,259** * Saturn acts as the investment manager for the Clients who hold the Shares described herein and referred to above. As a result, Saturn possesses the power to vote and dispose or direct the disposition of all the Shares beneficially owned by the Clients. No Client holds or beneficially owns five percent or more of the outstanding Shares of the Issuer. Saturn disclaims beneficial ownership of any of the Shares held by the Clients. ** Ms. Tian is the Managing Member of SVCM GP LLC, the general partner of Saturn, the Investment Manager of the Clients. As a result, Ms. Tian possesses the power to vote and dispose or direct the disposition of all the Shares beneficially owned by the Clients. Ms. Tian disclaims beneficial ownership of any of the Shares held by the Clients. † Based on a total of 34,558,709 shares outstanding of the Issuer as of November 30, 2023, as set forth in the Issuer’s most recent Form 10-Q, filed December 7, 2023. Item 5. If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be a beneficial owner of more than five percent of the class of securities, check the following: Item 6. This Item 6 is not applicable. CUSIP NO. 483497103 Page 7 of 7 Pages Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Co

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: February 12, 2024 Saturn V Capital Management LP By: /s/ Xiaoying Tian Name: Xiaoying Tian Title: Managing Member of SVCM GP LLC, the General Partner of Saturn V Capital Management LP Xiaoying Tian By: /s/ Xiaoying Tian Name: Xiaoying Tian

View Full Filing

View this SC 13G filing on SEC EDGAR